Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
REGN-6569 by Regeneron Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
REGN-6569 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...